Blinding
ADVERSE EVENT
The trial will be arranged and controlled by the research designer from the aspects of random number generation, allocation of experimental drug codes, experimental drug codes, registration of subjects, recording and evaluation of trial results, research monitoring, and data management. Both investigators and the subjects will be blinded. For the smooth implementation of the double-blinded trial, double-blinded simulation technology will be used to ensure that the provided placebo is identical to the actual duloxetine capsules in terms of dosage form, appearance, properties, smell, etc., but do not contain active ingredients. Both duloxetine capsules and placebo will be labeled with the name "duloxetine," along with the dosage, storage method, and drug number. Unblinding should be done only if the subject has a significant adverse event (SAE).